- Amneal Pharmaceuticals Inc (NYSE:AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million.
- Sales growth was driven by Generic product launches, specialty products Rytary & Unithroid, and overall volume growth within Generics and AvKARE segments.
- The gross margin expanded from 31% a year ago to 39.7%, buoyed by the Generics segment.
- Adjusted EPS almost doubled to $0.25, ahead of the consensus of $0.19.
- Amneal held cash and equivalents of $283.15 million at the end of Q2.
- Adjusted EBITDA was $151 million, an increase of 50% Y/Y reflective of net income growth.
- Outlook: Amneal maintains previously provided guidance for FY21 with sales of $2.1 billion – $2.2 billion (consensus $2.12 billion).
- It expects adjusted EBITDA of $500 million – $540 million and adjusted EPS of $0.70 – $0.85 (consensus $0.82).
- Price Action: AMRX shares closed at $4.87 on Friday.
Xcel Energy Names Bob Frenzel As New CEO
Xcel Energy Names Bob Frenzel as New CEO
Ben Fowke will remain as executive chairman and Tim O'Connor named EVP, chief operations officer
Xcel Energy announced today that Bob Frenzel has been appointed president